Entrar Registro gratuito

Hancock Jaffe Laboratories Inc Dívida/Patrimônio

Qual é o Dívida/Patrimônio de Hancock Jaffe Laboratories Inc?

O Dívida/Patrimônio de Hancock Jaffe Laboratories Inc é 0.48

Qual é a definição de Dívida/Patrimônio?



O índice de endividamento é um índice financeiro que indica a proporção relativa do patrimônio líquido e da dívida usada para financiar os ativos de uma empresa.

The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.

Dívida/Patrimônio de empresas na Setor Health Care em NASDAQ em comparação com Hancock Jaffe Laboratories Inc

O que Hancock Jaffe Laboratories Inc faz?

Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product candidates: the VenoValveÒ, a porcine-based valve which is intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency, and the CoreoGraftÒ, a bovine tissue-based off-the-shelf conduit intended to be used for coronary artery bypass surgery.

Empresas com dívida/patrimônio semelhantes a Hancock Jaffe Laboratories Inc